INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 175 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2014. The put-call ratio across all filers is 1.83 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,287,881 | +697.4% | 69,465 | +375.7% | 0.00% | – |
Q2 2023 | $161,510 | -8.7% | 14,603 | +10.8% | 0.00% | – |
Q1 2023 | $176,967 | -69.7% | 13,177 | -72.1% | 0.00% | – |
Q4 2022 | $584,397 | +46.5% | 47,243 | +64.8% | 0.00% | – |
Q3 2022 | $399,000 | -9.7% | 28,666 | -10.5% | 0.00% | – |
Q2 2022 | $442,000 | -18.9% | 32,016 | -4.4% | 0.00% | – |
Q1 2022 | $545,000 | +169.8% | 33,506 | +169.7% | 0.00% | – |
Q4 2021 | $202,000 | -3.3% | 12,422 | -11.6% | 0.00% | – |
Q3 2021 | $209,000 | -12.6% | 14,058 | +17.6% | 0.00% | – |
Q2 2021 | $239,000 | -69.7% | 11,951 | -4.7% | 0.00% | – |
Q1 2020 | $790,000 | -31.6% | 12,543 | +34.5% | 0.00% | – |
Q4 2019 | $1,155,000 | +11.5% | 9,323 | -40.3% | 0.00% | – |
Q3 2019 | $1,036,000 | +1.8% | 15,611 | +22.1% | 0.00% | – |
Q2 2019 | $1,018,000 | -9.2% | 12,790 | +27.7% | 0.00% | – |
Q1 2019 | $1,121,000 | +94.3% | 10,017 | +75.1% | 0.00% | – |
Q4 2018 | $577,000 | -72.3% | 5,721 | -65.3% | 0.00% | -100.0% |
Q3 2018 | $2,080,000 | +390.6% | 16,464 | +225.6% | 0.00% | – |
Q2 2018 | $424,000 | -43.9% | 5,057 | -58.8% | 0.00% | – |
Q1 2018 | $756,000 | +20.2% | 12,287 | +14.1% | 0.00% | – |
Q4 2017 | $629,000 | +72.8% | 10,766 | +71.4% | 0.00% | – |
Q3 2017 | $364,000 | -52.4% | 6,280 | -0.6% | 0.00% | – |
Q2 2017 | $765,000 | +11.4% | 6,316 | +4.0% | 0.00% | – |
Q1 2017 | $687,000 | +185.1% | 6,075 | +173.6% | 0.00% | – |
Q4 2016 | $241,000 | -15.4% | 2,220 | -0.1% | 0.00% | – |
Q1 2016 | $285,000 | -91.6% | 2,222 | -90.2% | 0.00% | -100.0% |
Q4 2015 | $3,374,000 | -36.0% | 22,593 | -28.9% | 0.00% | -50.0% |
Q3 2015 | $5,274,000 | +5.9% | 31,793 | +54.1% | 0.00% | 0.0% |
Q2 2015 | $4,979,000 | -30.7% | 20,626 | -19.0% | 0.00% | -33.3% |
Q1 2015 | $7,185,000 | -61.0% | 25,477 | -78.4% | 0.00% | -57.1% |
Q4 2014 | $18,431,000 | -5.1% | 118,151 | +43.9% | 0.01% | -12.5% |
Q3 2014 | $19,429,000 | +9.4% | 82,087 | +9.4% | 0.01% | +14.3% |
Q2 2014 | $17,759,000 | -49.6% | 75,049 | -29.8% | 0.01% | -50.0% |
Q1 2014 | $35,237,000 | +2561.4% | 106,848 | +457.3% | 0.01% | +1300.0% |
Q3 2013 | $1,324,000 | – | 19,173 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Samsara BioCapital, LLC | 234,375 | $23,623,000 | 22.67% |
Boxer Capital, LLC | 600,000 | $60,474,000 | 7.47% |
DLD Asset Management, LP | 834,600 | $84,136,000 | 5.77% |
GREAT POINT PARTNERS LLC | 200,000 | $20,158,000 | 2.55% |
BB BIOTECH AG | 575,719 | $58,027,000 | 1.86% |
Elk Creek Partners, LLC | 207,657 | $20,930,000 | 1.74% |
ALTRINSIC GLOBAL ADVISORS LLC | 277,944 | $28,014,000 | 1.34% |
Sarissa Capital Management LP | 54,000 | $5,442,000 | 1.21% |
QCM Cayman, Ltd. | 2,181 | $220,000 | 0.90% |
Opus Point Partners Management, LLC | 3,534 | $356,000 | 0.78% |